China has the world's largest number of world natural heritage sites, according to the National Forestry and Grassland Administration.

BULLHEAD CITY — A Frontier Communications outage is causing headaches for businesses, government agencies and organizations throughout Mohave County.

(The Center Square) — According to a report, the Louisiana Child Welfare division of the Department of Children and Family Services had 1,541 employees in 2024, serving over 4,000 children in foster ...

The Directorate of School Education has identified as many as 621 schools, primary to senior secondary, for de-notification, merger and downgrading due to zero or negligible enrolment. Education ...

American Embassy Locate American Embassy Embassy Consulate in Islamabad, Pakistan, for swift access. Discover contact numbers and the precise location for your convenience. Check comprehensive ...

On June 2, Kymera Therapeutics Inc. (NASDAQ:KYMR) announced positive first-in-human results from its Phase 1 healthy volunteer clinical trial of KT-621, which is a first-in-class, oral STAT6 degrader.

Kymera Therapeutics reported positive results from its phase 1 healthy volunteer study using KT-621. Click here to find out why KYMR stock is a Strong Buy.

Kymera Therapeutics (KYMR) announced Monday positive Phase 1 results from its healthy volunteer study of KT-621, a first-in-class oral STAT6 degrader, sending shares up +35% in premarket trading.

Kymera Therapeutics shares rose after it disclosed positive clinical results from the Phase 1 healthy volunteer study of KT-621. Shares were up 13% to $33.49 in premarket trading on Monday.

Kymera's KT-621 shows promising STAT6 degradation in Phase 1 trials, with favorable safety and planned further studies in 2025. Quiver AI Summary Kymera Therapeutics announced encouraging results ...

Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader ...

Phase 1 healthy volunteer data of KT-621, a once-a-day STAT6 degrader, surpass Kymera’s target product profile, significantly derisking program and further validating its oral, biologics-like ...